Lerner Research Institute News

Read about the latest advances from Lerner Research Institute scientists, including new findings, grant awards, innovations and collaborations.

Cleveland Clinic Appoints Key Leadership to Center for Immunotherapy & Precision Immuno-Oncology

J. Joseph Melenhorst, PhD, has been appointed director of the new Cell Therapy and Immuno-Engineering Program, and Vice Chair of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic.

03/15/2022




J. Joseph Melenhorst, PhD, has been appointed director of the new Cell Therapy and Immuno-Engineering Program, and Vice Chair of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic.

A renowned cancer immunology expert, Dr. Melenhorst will lead the cell therapy developmental therapeutics program, with a focus on translating research into novel cellular therapies for patients. As vice chair of the Center for Immunotherapy and Precision Immuno-Oncology, he will work with experts from across Cleveland Clinic to advance research and treatment related to the rapidly growing field of immuno-oncology.

“Immunotherapy is the future of research in cancer and various other diseases, and Cleveland Clinic has made it a priority to establish a leading cell therapy program,” said Timothy Chan, MD, PhD, chair of Cleveland Clinic’s Center for Immunotherapy and Precision Immuno-Oncology. “The program will empower clinicians and scientists to advance personalized cellular immunotherapy and further distinguish the Cleveland area as a top hub for cellular therapy development.”

Dr. Melenhorst joins Cleveland Clinic from University of Pennsylvania where he was a senior member of the Center for Cellular Immunotherapies for almost a decade. There, he was instrumental in helping bring cell therapies such as chimeric antigen receptor T cell (CAR-T) therapy into patient care. CAR-T therapy has revolutionized cancer care. His research spans basic and translational immunology with an emphasis on developing next generation immune-oncology treatments and related translational sciences. His efforts also focus on the immunobiology of CAR-T cell therapies to more safely and effectively target cancers. 

Dr. Melenhorst received his Ph.D. from the University of Leiden, Netherlands.

View press release in Cleveland Clinic Newsroom.




Looking for more news and updates from Lerner Research Institute? Check out our news archive.

View Archive

Looking for more news and updates from Cleveland Clinic? Check out the Cleveland Clinic Newsroom.

Cleveland Clinic News Feed